{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02620553",
      "orgStudyIdInfo": {
        "id": "05-1043"
      },
      "organization": {
        "fullName": "University of Colorado, Denver",
        "class": "OTHER"
      },
      "briefTitle": "Primary Intervention With Mucosal Insulin",
      "officialTitle": "Primary Intervention With Mucosal Insulin for Prevention of Type 1 Diabetes in Infants at High Genetic Risk to Develop Diabetes POINT (Primary Oral Insulin Trial) A Dose Finding and Safety Study ( Pre-POINT )",
      "acronym": "Pre-POINT"
    },
    "statusModule": {
      "statusVerifiedDate": "2017-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2007-09"
      },
      "primaryCompletionDateStruct": {
        "date": "2013-06",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2014-01",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-06-08",
      "studyFirstSubmitQcDate": "2015-11-30",
      "studyFirstPostDateStruct": {
        "date": "2015-12-03",
        "type": "ESTIMATED"
      },
      "dispFirstSubmitDate": "2015-12-18",
      "dispFirstSubmitQcDate": "2017-04-19",
      "dispFirstPostDateStruct": {
        "date": "2017-04-20",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2017-04-19",
      "lastUpdatePostDateStruct": {
        "date": "2017-04-20",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "University of Colorado, Denver",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "University Hospital Dresden",
          "class": "OTHER"
        },
        {
          "name": "Diabetes Research Institute, Munich, Germany.",
          "class": "UNKNOWN"
        },
        {
          "name": "University of Bristol",
          "class": "OTHER"
        },
        {
          "name": "Juvenile Diabetes Research Foundation",
          "class": "OTHER"
        },
        {
          "name": "German Federal Ministry of Education and Research",
          "class": "OTHER_GOV"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "A dose with proven drug bioavailability to the immune system for use in a phase II/III primary T1DM (type 1 diabetes) vaccination trial (POINT study) in genetically at risk subjects.\n\nStudy Design Randomized, placebo-controlled, double-blind/double-masked, multi-center, dose escalation primary intervention pilot study.\n\nAccrual Objective 25 (3:2 randomization to active and control arms)",
      "detailedDescription": "The objective of this study is to determine the feasibility, safety and bioavailability of oral insulin in children with high genetic risk for T1DM in a dose escalation primary intervention pilot study."
    },
    "conditionsModule": {
      "conditions": [
        "Type 1 Diabetes"
      ],
      "keywords": [
        "Type 1 Diabetes",
        "Diabetes",
        "Autoimmune Diabetes"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "PREVENTION",
        "maskingInfo": {
          "masking": "TRIPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 25,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Human Insulin",
          "type": "EXPERIMENTAL",
          "description": "Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day",
          "interventionNames": [
            "Drug: Human Insulin"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Oral Placebo",
          "interventionNames": [
            "Other: Oral Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Human Insulin",
          "description": "There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)",
          "armGroupLabels": [
            "Human Insulin"
          ],
          "otherNames": [
            "Oral Insulin"
          ]
        },
        {
          "type": "OTHER",
          "name": "Oral Placebo",
          "description": "Oral Placebo is given orally daily",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Change in Blood Glucose Levels",
          "description": "Evaluation for hypoglycemia will be measured prior to administration of the insulin (baseline), then at 30, 60, and 120 minutes after administration of the insulin.",
          "timeFrame": "Day 1"
        },
        {
          "measure": "Daily Evaluation of Blood Glucose Levels",
          "description": "Blood glucose will be measured 60 minutes after the administration of the Insulin.",
          "timeFrame": "Days 2 through 7"
        },
        {
          "measure": "Evaluation of Blood Glucose Levels",
          "description": "After treatment day 7, Insulin will be administered and measured on a monthly basis.",
          "timeFrame": "Measured 60 minutes after oral insulin dosing, every day during each 4th week, as long as the subject is given oral insulin."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change in Total IgE and IgE.",
          "description": "Allergy/intolerance to the study drug evaluated with total IgE and IgE antibodies to insulin at 2 weeks, 3 months, 6 months, then every 6 months thereafter, as well as monitored through self-reporting by families. Parents/guardians will be educated on and instructed to look out for possible allergic reactions to insulin.",
          "timeFrame": "2 weeks, 3 months, 6 months"
        },
        {
          "measure": "T-cell responses related to potential immune response to Insulin",
          "description": "T-cell responses e.g. antibody and cell mediated immune results will be evaluated the day of administration then at 15 days, 3 and 6 months, and every 6 months of treatment, and will be reported directly to the Data Coordinating Center.",
          "timeFrame": "Day 1, 15 days, 3 and 6 months."
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Children aged 2 years to 7 years who:\n\n   * Have a multiplex first degree family history of T1DM (both parents, parent and sib, or two sibs);\n   * Type 1 diabetes susceptible HLA DR4-DQB1\\*0302 or DR4-DQB1\\*0304 haplotype and\n\n   None of the following HLA DR or DQB1 alleles:\n   * DR 11\n   * DR 12\n   * DQB1\\*0602\n   * DR7-DQB1\\*0303\n   * DR14-DQB1\\*0503 or\n   * Have a sibling with T1DM;\n   * Identical by descent for the HLA DR3/DR4-DQ8 genotype with their diabetic sibling;\n2. Islet autoantibody negative at time of recruitment.\n\nExclusion Criteria:\n\n1. Children with any kind of congenital or acquired chronic disease that potentially interfere with the study objectives.\n2. Prior or current participation in another intervention trial.\n3. Chronic oral steroid use and/or other chronic oral immunosuppressant",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "2 Years",
      "maximumAge": "7 Years",
      "stdAges": [
        "CHILD"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ezio Bonifacio, PhD",
          "affiliation": "Medical Faculty Carl Gustav Carus, Dresden University of Technology",
          "role": "PRINCIPAL_INVESTIGATOR"
        },
        {
          "name": "Georgeanna J Klingensmith, MD",
          "affiliation": "University of Colorado, Denver",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Barbara Davis Center for Childhood Diabetes",
          "city": "Aurora",
          "state": "Colorado",
          "zip": "80045",
          "country": "United States",
          "geoPoint": {
            "lat": 39.72943,
            "lon": -104.83192
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "25898052",
          "type": "RESULT",
          "citation": "Bonifacio E, Ziegler AG, Klingensmith G, Schober E, Bingley PJ, Rottenkolber M, Theil A, Eugster A, Puff R, Peplow C, Buettner F, Lange K, Hasford J, Achenbach P; Pre-POINT Study Group. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015 Apr 21;313(15):1541-9. doi: 10.1001/jama.2015.2928."
        }
      ],
      "seeAlsoLinks": [
        {
          "label": "Pre-POINT",
          "url": "http://www.diabetes-point.org/uk.html"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003922",
          "term": "Diabetes Mellitus, Type 1"
        },
        {
          "id": "D003920",
          "term": "Diabetes Mellitus"
        }
      ],
      "ancestors": [
        {
          "id": "D044882",
          "term": "Glucose Metabolism Disorders"
        },
        {
          "id": "D008659",
          "term": "Metabolic Diseases"
        },
        {
          "id": "D009750",
          "term": "Nutritional and Metabolic Diseases"
        },
        {
          "id": "D004700",
          "term": "Endocrine System Diseases"
        },
        {
          "id": "D001327",
          "term": "Autoimmune Diseases"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D007328",
          "term": "Insulin"
        }
      ],
      "ancestors": [
        {
          "id": "D011384",
          "term": "Proinsulin"
        },
        {
          "id": "D061385",
          "term": "Insulins"
        },
        {
          "id": "D010187",
          "term": "Pancreatic Hormones"
        },
        {
          "id": "D036361",
          "term": "Peptide Hormones"
        },
        {
          "id": "D006728",
          "term": "Hormones"
        },
        {
          "id": "D006730",
          "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
        },
        {
          "id": "D010455",
          "term": "Peptides"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        }
      ]
    }
  },
  "hasResults": false
}